Found: 9
Select item for more details and to access through your institution.
Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 777, doi. 10.1007/s40273-015-0274-y
- By:
- Publication type:
- Article
Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 783, doi. 10.1007/s40273-015-0267-x
- By:
- Publication type:
- Article
The Economic Costs of Type 2 Diabetes: A Global Systematic Review.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 811, doi. 10.1007/s40273-015-0268-9
- By:
- Publication type:
- Article
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 833, doi. 10.1007/s40273-015-0272-0
- By:
- Publication type:
- Article
Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 849, doi. 10.1007/s40273-015-0275-x
- By:
- Publication type:
- Article
Characterizing Heterogeneity Bias in Cohort-Based Models.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 857, doi. 10.1007/s40273-015-0273-z
- By:
- Publication type:
- Article
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE).
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 867, doi. 10.1007/s40273-015-0292-9
- By:
- Publication type:
- Article
Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 879, doi. 10.1007/s40273-015-0278-7
- By:
- Publication type:
- Article
The Silence in Hoch et al.'s Commentary about the Rationale for and Objective(s) of Canada's Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers' Dollars.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 8, p. 883, doi. 10.1007/s40273-015-0297-4
- By:
- Publication type:
- Article